Related coverage linked through entity extraction aliases.
Mar 07, 2026
Moffitt Cancer Center researchers published findings on plant-based diets and cancer risk, identified spatial tumor-immune patterns predicting immunotherapy response, and hosted a summit on engineering-driven cancer research innovations.
Mar 05, 2026
New research reveals that different KRAS mutation types create distinct tumor ecosystems with varying immune responses, potentially enabling personalized treatment strategies combining mutation-specific inhibitors with immunotherapy.
Feb 27, 2026
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
Feb 20, 2026
The clinical trials industry is expected to grow from $61.93 billion in 2025 to $99.25 billion by 2033 at a 6.07% CAGR, driven by demand for innovative therapies and chronic disease prevalence. Clinical trials management systems are projected to reach $9.0 billion by 2035.
Feb 18, 2026
OncoHost announced publication of a study in JPBA introducing a computational framework that harmonizes serum and plasma proteomic datasets, enabling researchers to combine previously incompatible specimen types for biomarker research.
Feb 18, 2026
Researchers at The University of Texas MD Anderson Cancer Center developed a computational approach using tumor-specific total mRNA expression (TmS) that outperformed current methods for predicting chemotherapy response in triple-negative breast cancer patients.
Feb 16, 2026
Scientists at UC San Diego have identified N4BP2 as the enzyme responsible for chromothripsis, a chaotic chromosome-shattering event seen in about one in four cancers that enables rapid tumor evolution and treatment resistance.
Feb 18, 2026
Sylvester Comprehensive Cancer Center has developed OncoPRO, a next-generation symptom monitoring program that embeds patient-reported outcomes directly into electronic medical records to detect problems earlier and strengthen patient safety in cancer care.
Feb 17, 2026
NYU Langone Health researchers discover pancreatic cancer cells toggle between rapid growth and chemotherapy resistance based on their proximity to extracellular matrix fibers, complicating single-drug treatment approaches.
Feb 13, 2026
The FDA has approved Optune Pax, a wearable device delivering tumor treating fields for locally advanced pancreatic cancer. The approval marks the first new treatment modality for this indication in nearly 30 years.
